“We are delighted to welcome Charlie and James,” said Managing Partner Martin Fletcher.  “Together, they are a formidable addition to an already deep litigation bench.  Each also brings significant experience in the field of maritime law, growing our capabilities in that sector measurably.”

With nearly 25 years of experience as a litigator and trial lawyer, Mr. Simmons’ practice extends across business, commercial and insurance defense litigation, as well as insurance coverage, intellectual property, and maritime and construction law. He has significant experience in maritime law, including maritime insurance matters, and teaches maritime law at the University of Baltimore. He also has substantial in-court trial experience representing individuals who have suffered serious injury.

Mr. Jeffcoat is experienced in civil litigation in federal and state courts, including commercial litigation, insurance coverage and defense, admiralty and maritime disputes, and intellectual property litigation. He also has experience with patent infringement actions, including before the International Trade Commission. His practice includes in-court trial experience representing individuals who have suffered serious injury.

Said Mr. Simmons, “We’re excited to join Whiteford.  It’s a compelling, full service platform for serving our clients and, at the same time, expanding our practices.”

About Whiteford, Taylor & Preston LLP
With over 175 attorneys, Whiteford, Taylor & Preston provides a comprehensive range of sophisticated, cost-effective business law and litigation services to clients ranging from innovative start-ups to middle market companies to global enterprises.  Our growing Mid-Atlantic footprint includes sixteen offices in Delaware, D.C., Kentucky, Maryland, Michigan, New York, Pennsylvania and Virginia.

If you are a U.S.-based company, send an email to resource.mema@maryland.gov. Please include company name and address and point-of-contact (email and phone number).

If you are an international-based company, please reach out to the Commerce International Trade and Investment Team member who represents your region. Please provide company name and address and point-of-contact (email and phone number).

• East Asia – Felicia Pullam | felicia.pullam@maryland.gov 
• Africa, Middle East & South Asia – Brian Castleberry | brian.castleberry@maryland.gov 
•  The Americas – Michael Howley | michael.howley@maryland.gov
•  Europe, Australia & New Zealand – Andrew Kreinik | andrew.kreinik@maryland.gov

THEN, COMPLETE THE RFI.

Please complete the RFI online.

Please consider the following information before completing the steps above.

1. We do not provide resource request lists but do accept summaries from companies offering goods and services. Please compile a detailed list and an appropriate command staff member will vet your company’s credentials.
2. All suppliers must be vetted before being entered into the Emergency Supplier Database so please discourage middlemen and consultants from contacting MEMA, and instead, have them pass this information to the supplier.

For any further questions, please contact Ernesto Chanona (ernesto.chanona@maryland.gov) with the Office of BioHealth and Life Sciences.

License Renewal Extensions
In accordance with the Governor’s order that license periods will be extended for 30 days beyond the declared state of emergency, the deadline to submit an alcoholic beverages license renewal application and the deadline to pick up the renewed license will be extended. Licensees will be informed once new deadlines have been established.

For those wishing to submit the renewal application now, paper applications with a check can be mailed to LRE, 201 Edison Park Drive, Gaithersburg, MD 20878. Applications can also be submitted through the online portal. Use your existing iStore account or create a new account.

Carryout/Delivery Permission for RESTAURANTS
The Board of License Commissioners approved the following resolution authorizing restaurants to sell beer and wine for carryout or delivery with a meal:  While the Governor’s order to close all restaurants as a part of the catastrophic health emergency remains in effect, all restaurants licensed by the Montgomery County Board of License Commissioners may sell sealed containers of beer and wine for off-premises consumption along with a takeout or delivered meal. This permission includes the sale of bottles, cans, growlers, and crowlers for off-premises consumption and does not include the sale of alcoholic drinks in a to-go cup. This permission does not include liquor. This permission expires when the emergency order to close restaurants is lifted. Businesses may deliver beer and wine to Montgomery County addresses along with a meal using their own staff. State law prohibits the delivery of alcohol by a third party, such as Grubhub or Uber Eats. Businesses must apply for this permission through an online form, and permission will be granted administratively by Alcohol Beverage Services staff.

Apply for the permission at:  https://myabs.formstack.com/forms/restaurant_offpremise_permission.

Delivery Permit for BEER and WINE STORES
The Board of License Commissioners has authorized expedited approval of applications for a Retail Delivery permit by for Class BBWHR, ABW, BDBWL, and DBW licenses.

Apply for the permit at www.montgomerycountymd.gov/ABS/Resources/Files/licensure/abs-retail-delivery-application.pdf.

Get the regulations at www.montgomerycountymd.gov/ABS/Resources/Files/licensure/abs-off-premise-delivery-written-ceftification.pdf.

For Orders and Deliveries
ABS has cancelled all open sales orders and open purchase orders for on-premise only accounts due to Governor Hogan’s executive order to close all restaurants and bars (with the exception of carry-out, drive-thru and delivery service). With the new permissions for a delivery permit for on-premise licensees, any items that your account would like will need to be re-ordered through:

• iStore,
• emailing ABS.CommunicationCenter@montgomerycountymd.gov, or
• by fax at 240-777-1909.

Please keep in mind that ABS has implemented a minimum delivery of five cases of wine/spirit and seven cases of beer during this pandemic.

GAITHERSBURG, Md., Feb. 28, 2020 (GLOBE NEWSWIRE) — Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced the advancement of a novel single-dose, intranasal vaccine using Altimmune’s proprietary technology to protect against COVID-19, the disease caused by the SARS-CoV-2 virus. Altimmune has completed the design and synthesis of the vaccine and is now advancing it toward animal testing and manufacturing.

“With the spread of COVID-19 outside of China, including the first case of unknown origin in the United States, we have taken action to develop and make our vaccine technology available to help address this crisis,” said Vipin K. Garg, Ph.D., President and Chief Executive Officer of Altimmune. “We believe that our intranasal vaccine technology is especially well suited to provide systemic protection against respiratory infections that affect the upper and lower airways and can therefore be a useful tool in preventing further spread of COVID-19. As such, we are actively engaged in discussions with a number of potential partners.”

The new intranasal vaccine is based on the same platform vaccine technology as NasoVAX, the company’s influenza vaccine candidate. Like NasoVAX, the COVID-19 vaccine is designed to provide systemic immunity following a single intranasal dose. A recent Phase 2 clinical study with NasoVAX highlighted the ability of intranasal vaccine delivery to stimulate a durable and broad immune response against the influenza virus.

Altimmune believes the clinical profile of NasoVAX is particularly relevant to COVID-19 because intranasal delivery directs the immune response where it is needed most to protect against respiratory infection, including the likely site of initial viral attack. Clinical testing of the vaccine could begin as early as August.

UPDATE:  March 30, 2020–Altimmune and The University of Alabama at Birmingham to Collaborate on Development of Single-Dose, Intranasal COVID-19 Vaccine.

About Altimmune
Altimmune is a clinical stage biopharmaceutical company focused on developing treatments for liver disease, immune modulating therapies and vaccines. Our diverse pipeline includes next generation peptide therapeutics for NASH (ALT-801) and chronic hepatitis B (HepTcell™), conjugated immunostimulants for the treatment of cancer (ALT-702) and intranasal vaccines (NasoVAX™, NasoShield™ and AdCOVID™). For more information on Altimmune, please visit www.altimmune.com.